➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Johnson and Johnson
McKesson
McKinsey
AstraZeneca

Last Updated: September 19, 2020

DrugPatentWatch Database Preview

Patent: 9,084,815

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,084,815
Title:Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
Abstract: Disclosed is a method for treating tumor in a mammalian subject, which comprises administering a combination of (a) an anti-tumor agent and (b) a fatty acid derivative represented by the formula (I): ##STR00001## to the subject in need thereof. The application also discloses a method for treating damages, especially gastrointestinal damages including mucositis such as stomatitis induced by an anti-tumor agent, wherein the method comprises administering a fatty acid derivative of formula (I) to the subject who is receiving the anti-tumor agent.
Inventor(s): Ueno; Ryuji (Montgomery, MD)
Assignee: SUCAMPO AG (Zug, CH)
Application Number:12/882,794
Patent Claims:see list of patent claims

Details for Patent 9,084,815

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial SUCAMPO AG (Zug, CH) 2029-09-16 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial SUCAMPO AG (Zug, CH) 2029-09-16 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial SUCAMPO AG (Zug, CH) 2029-09-16 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial SUCAMPO AG (Zug, CH) 2029-09-16 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial SUCAMPO AG (Zug, CH) 2029-09-16 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Colorcon
Dow
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.